{"id":31458,"date":"2026-10-26T04:57:00","date_gmt":"2026-10-25T20:57:00","guid":{"rendered":"https:\/\/csccm.org.cn\/?p=31458"},"modified":"2026-10-26T05:43:08","modified_gmt":"2026-10-25T21:43:08","slug":"jama%e5%8f%91%e8%a1%a8%e8%ae%ba%e6%96%87%ef%bc%9aldl-c%e5%8d%87%e9%ab%98%e7%9a%84%e5%85%a8%e7%90%83%e8%b4%9f%e6%8b%85","status":"publish","type":"post","link":"https:\/\/csccm.org.cn\/?p=31458","title":{"rendered":"[JAMA\u53d1\u8868\u8bba\u6587]\uff1aLDL-C\u5347\u9ad8\u7684\u5168\u7403\u8d1f\u62c5"},"content":{"rendered":"\n

Original Investigation <\/p>\n\n\n\n

Global Burden of Disease<\/p>\n\n\n\n

Global Burden of Elevated LDL-C: Findings From the Global Burden of Disease Study 2023<\/h1>\n\n\n\n

GBD 2023 LDL Cholesterol Collaborators<\/h3>\n\n\n\n

JAMA Published Online: July 29, 2026<\/h3>\n\n\n\n

2026;336;(8):673-698<\/h3>\n\n\n\n

doi: 10.1001\/jama.2026.8628<\/h3>\n\n\n\n

Key Points<\/p>\n\n\n\n

Question<\/strong>  What is the global disease burden attributable to elevated low-density lipoprotein cholesterol (LDL-C)?<\/p>\n\n\n\n

Findings<\/strong>  In 2023, high LDL-C caused 3.6 million deaths (6.0% of all deaths) and 90.7 million disability-adjusted life years (DALYs) (3.2% of total DALYs). Despite declines of 45.6% in age-standardized mortality rates and 39.5% in DALY rates, the absolute LDL-C\u2013related burden increased by 38.5% from 1990 to 2023, driven by population growth and aging, with notable regional disparities shifting toward middle-sociodemographic settings.<\/p>\n\n\n\n

Meaning<\/strong>  Strategic approaches to prevent, diagnose, and treat elevated LDL-C across populations globally are needed.<\/a><\/p>\n\n\n\n

Abstract<\/p>\n\n\n\n

Importance<\/strong>  Elevated low-density lipoprotein cholesterol (LDL-C) is a modifiable risk factor for cardiovascular disease, the leading cause of premature death worldwide. Assessing the LDL-C\u2013related burden is critical for guiding prevention and treatment strategies.<\/p>\n\n\n\n

Objectives<\/strong>  To estimate the global, regional, and national burden of ischemic heart disease and ischemic stroke attributable to elevated LDL-C (relative to 35-54 mg\/dL) from 1990 to 2023 and to quantify the contributions of population growth, aging, risk-deleted burden, and exposure changes to burden trends.<\/p>\n\n\n\n

Design, Setting, and Population<\/strong>  This comparative risk assessment, part of the Global Burden of Disease Study 2023, estimated population-level LDL-C exposure and associated health loss in 204 countries and territories. Mean LDL-C levels were estimated using spatiotemporal gaussian process regression based on 806 studies across 161 countries. Relative risks were derived from meta-analyses of 38 randomized clinical trials. Population-attributable fractions for deaths and disability-adjusted life-years (DALYs) were estimated by age and sex for adults aged 25 years or older from 1990 to 2023, with 95% uncertainty intervals.<\/p>\n\n\n\n

Exposure<\/strong>  Population-level LDL-C concentrations.<\/p>\n\n\n\n

Main Outcomes and Measures<\/strong>  Population-attributable fractions, counts, and rates (all ages and age standardized per 100\u202f000) of LDL-C\u2013attributable deaths and DALYs from ischemic heart disease and ischemic stroke, with uncertainty intervals.<\/p>\n\n\n\n

Results<\/strong>\u00a0\u00a0In 2023, elevated LDL-C accounted for 3.6 million deaths (95% uncertainty interval, 2.2-5.4 million; 6.0% of global mortality) and 90.7 million DALYs (95% uncertainty interval, 58.9-123.3 million; 3.2% of DALYs). Although global all-ages rates remained stable, age-standardized death and DALY rates decreased by 45.6% and 39.5%, respectively, since 1990. In 2023, age-standardized LDL-C\u2013attributable DALY rates were highest in Eastern Europe and lowest in high-income Asia-Pacific. One-third of the global LDL-C burden occurred in India and China. Population growth and aging drove the increasing burden, with notable regional disparities in LDL-C exposure and risk-deleted DALY rates shifting toward middle-sociodemographic settings.<\/p>\n\n\n\n

\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n

Conclusions and Relevance<\/strong>  Despite declining age-standardized rates, the absolute LDL-C burden has increased since 1990 due to demographic changes and has shifted toward middle-sociodemographic countries. Measurement and surveillance gaps persist. Strengthened prevention, diagnosis, and treatment access strategies are essential to mitigate the health burden of LDL-C.<\/p>\n","protected":false},"excerpt":{"rendered":"

Original Investigation  Global Burden of Disease G […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[32],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/31458"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31458"}],"version-history":[{"count":3,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/31458\/revisions"}],"predecessor-version":[{"id":31851,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/31458\/revisions\/31851"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31458"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31458"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31458"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}